Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
October 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
UChicago Medicine Comprehensive Cancer Center

UChicago Annual Updates from ASH 2019

Fri, Feb 28, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
09:02
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

15:31
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
17:58
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relapse? No!

Feat. J. Mikhael
06:23
Parameswaran Hari

Treating Refractory & Relapsing Myeloma: Current Trends and Recommendati...

17:47
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. Raje
33:59
Roswell Park Comprehensive Cancer Center

Minimal Residual Disease (MRD) Testing in Multiple Myeloma. How and When...

Feat. P. McCarthy